Biochemia medica最新文献

{"title":"Levothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism.","authors":"Tihana Serdar Hiršl, Koraljka Đurić, Marina Čeprnja, Ivana Zec, Marijana Kraljević Šmalcelj, Tomislav Jukić, Tanja Bobetić-Vranić, Anita Somborac-Bačura","doi":"10.11613/BM.2025.010703","DOIUrl":"10.11613/BM.2025.010703","url":null,"abstract":"<p><strong>Introduction: </strong>Subclinical hypothyroidism (SCH) is an independent risk factor for cardiovascular diseases due to endothelial dysfunction and atherosclerosis development. The aim of this study was to determine whether the levothyroxine therapy could impact the concentrations of endothelial dysfunction blood markers, namely endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA) and endocan, in patients with a mild form of SCH (thyroid-stimulating hormone (TSH) ≤ 10 mIU/L).</p><p><strong>Materials and methods: </strong>In this case-control prospective study, SCH patients and healthy controls were recruited during their regular health examinations. Medical specialists prescribed levothyroxine to SCH patients if necessary. The endothelial dysfunction markers, as well as other biochemical markers, were measured in all subjects at baseline, and after 6 months of levothyroxine treatment following the euthyroidism.</p><p><strong>Results: </strong>Our study showed higher ADMA (248.00 (168.78-540.20) <i>vs</i>. 166.30 (140.60-243.40) μg/L, P = 0.002), endocan (114.30 (63.45-194.65) <i>vs</i>. 67.26 (50.80-126.10) ng/L, P = 0.004), low-density lipoprotein cholesterol (LDL) (3.3 ± 0.6 <i>vs</i>. 3.7 ± 0.9 mmol/L, P = 0.043) and non-high-density lipoprotein cholesterol (non-HDL) (3.8 ± 0.7 <i>vs</i>. 4.2 ± 1.0 mmol/L, P = 0.020) concentrations in patients with a mild form of SCH in comparison with healthy subjects. In SCH patients, after 6 months of levothyroxine treatment following the euthyroidism, we observed a significant decrease in endocan (91.47 (61.88-200.03) <i>vs</i>. 97.90 (55.18-154.88) ng/L, P = 0.004), and total cholesterol concentrations (CHOL) (6.2 ± 1.0 <i>vs</i>. 5.8 ± 1.0 mmol/L, P = 0.039).</p><p><strong>Conclusions: </strong>A mild form of SCH is associated with higher concentrations of endocan, ADMA, LDL and non-HDL. The potential benefits of levothyroxine therapy were shown through the significant decrease of endocan and CHOL concentrations in SCH patients, thus contributing the atherosclerosis prevention.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposal for delta check limits of frequently requested hormones using real-world data.","authors":"Sunghwan Shin, Shinae Yu, Sollip Kim, Soo Jin Yoo, Eun-Jung Cho, Jae-Woo Chung","doi":"10.11613/BM.2025.010704","DOIUrl":"10.11613/BM.2025.010704","url":null,"abstract":"<p><strong>Introduction: </strong>Research on delta check limits (DCLs) for hormones is limited, yet some laboratories apply arbitrary DCLs. We aimed to propose DCLs for commonly requested hormones.</p><p><strong>Materials and methods: </strong>This study analyzed 59,657 paired results for adrenocorticotropic hormone (ACTH), cortisol, parathyroid hormone (PTH), prolactin, insulin, testosterone, and thyroglobulin from five Korean university hospitals. Delta check limits were established using the absolute delta difference (absDD) and absolute delta percent change (absDPC) with 5% cutoff for inpatients/emergencies (IE), outpatients (O) and both (combined; mean of them). Proportions outside the DCLs were compared across groups.</p><p><strong>Results: </strong>Using absDD and absDPC, each group's DCLs showed 4.3% to 6.4% of values outside the DCLs, aligning with the 5% cutoff (excluding group IE for insulin, testosterone, and thyroglobulin due to < 1000 data pairs). Delta check limits of absDD differed between groups for ACTH, cortisol, PTH, and prolactin, while for absDPC, differences were seen only for ACTH and prolactin. Cross-validation revealed IE and O groups differed outside DCLs of absDD for ACTH, cortisol, and PTH, but only ACTH with absDPC. Combined DCLs of absDD showed ACTH and cortisol exceeded limits in 7.2% and 9.0% in IE, but only 2.6% and 0.6% in O. With absDPC, ACTH differed (10.4% in IE, 2.8% in O), while cortisol, PTH, and prolactin ranged from 4.0% to 6.1%.</p><p><strong>Conclusions: </strong>Combined DCLs of absDPC are recommended for cortisol, PTH, and prolactin, while ACTH requires separate DCLs on clinical settings. These DCLs from real-world data provide a foundation for establishing DCLs of hormones in clinical laboratories.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010704"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of new Westgard rules suggested by the Westgard Advisor software for five immunological parameters.","authors":"Lisa Cristelli, Francesca Occhipinti, Daniel Tumiatti, De Luisi Antonia, Erika Jani, Massimo Daves","doi":"10.11613/BM.2025.010701","DOIUrl":"10.11613/BM.2025.010701","url":null,"abstract":"<p><strong>Introduction: </strong>Knowledge and systematic evaluation of analytical errors is the task of internal analytical quality control management. The aim of this study was to assess whether the Westgard rules proposed by Bio-Rad's Westgard Advisor software are more efficient in the monitoring of analytical performance than those previously in use.</p><p><strong>Materials and methods: </strong>The study was carried out on the nephelometer Atellica NEPH630 (Siemens Healthineers, Erlangen, Germany). Five parameters were chosen: serum immunoglobulin A (IgA), alpha 1 - antitrypsin (AAT), prealbumin, lipoprotein (a) (Lp(a)) and ceruloplasmin. The study was divided into 4 phases (A, B, C, D): phase A - old rules used (1_3s, R_4s and 2_2s); phase B - first introduction of new rules (30 days), (1_3s/2_2s for IgA; 1_3s/2_2s/R_4s/4_1s/10_x for the remaining parameters); Phase C - second intervention (after 60 days) 1_3s/2_2s/R_4s/4_1s for IgA and Lp(a), 1_3s/2_2s/R_4s/4_1s/8_x for prealbumin and ceruloplasmin and 1_3s/2_2s/R_4s/4_1s/10_x for AAT; and Phase D - values at the end of the study (1_3s for IgA, 1_3s/2_2s/3_2s/R_4s/3_1s/12_x for AAT and ceruloplasmin, 1_3s/2_2s/R_4s/4_1s/8_x for prealbumin and 1_3s/2_2s/R_4s/4_1s/10_x for Lp(a).</p><p><strong>Results: </strong>At the end of the study the coefficient of variation (CV%), bias (%) and sigma for IgA were 2.55%, - 1.09% and 5.33, respectively; for AAT 3.88, - 2.21 and 3.25; for prealbumin 3.99, - 0.14 and 2.95; for Lp(a) 8.02, - 0.34 and 3.81; for ceruloplasmin 2.48, - 3.65 and 3.49.</p><p><strong>Conclusions: </strong>By using newly suggested rejection rules, we did not observe an improvement in monitoring of analytical performance.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010701"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers.","authors":"Gramos Begolli, Maja Lukić, Lada Rumora, Lorna Čorak, Andrea Vukić Dugac, Marko Jakopović, Miroslav Samaržija, Ilijan Tomaš, Jelena Knežević, Željko Debeljak","doi":"10.11613/BM.2025.010702","DOIUrl":"10.11613/BM.2025.010702","url":null,"abstract":"<p><strong>Introduction: </strong>Higher concentrations of the small-cell lung cancer (SCLC) serum marker, pro-gastrin-releasing peptide (proGRP), in lung inflammations has been indicated in literature. The objective of this study was to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD) and early-stage primary lung cancers.</p><p><strong>Materials and methods: </strong>An observational study was performed to assess serum proGRP against other lung cancer markers in pneumonia, COPD and in stage 1/2 carcinomas. A total of 91 cases of pneumonia or chronic obstructive pulmonary disease (COPD), with 107 cases of early-stage lung adenocarcinoma (ADC), squamous cell carcinoma (SQCC) and 14 cases of neuroendocrine tumors (NET), including SCLC, were analyzed. Serum proGRP (Roche Diagnostics, Basel, Switzerland), cytokeratin 19 fragment 21-1, carcinoembryonic antigen, neuron-specific enolase and C-reactive protein were measured and compared. For the statistical analysis, Mann-Whitney U test, Kruskal-Wallis ANOVA, multiple linear and multinomial logistic regression modeling were used.</p><p><strong>Results: </strong>Compared to the early-stage ADC and SQCC, proGRP in pneumonia, COPD and in NET was higher (P ≤ 0.011 in all comparisons). In 11 cases of pneumonia and COPD, proGRP reached cut-off for SCLC of 100 ng/L. No clinically relevant differences between pneumonia or COPD and early-stage cancer were observed for other markers. Concentration of proGRP was associated with CRP (model coefficient was 0.20; P < 0.019) and both parameters contributed to classification of cases to pneumonia/COPD, ADC/SQCC, and NET categories (P < 0.004, in all cases).</p><p><strong>Conclusions: </strong>Concentrations of proGRP in pneumonia and COPD patients were higher than in patients in the ADC and SQCC early stages and could exceed the SCLC cut-off.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010702"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological variation of thyroid stimulating hormone, free triiodothyronine and free thyroxine in healthy subjects in Turkey.","authors":"Raziye Yıldız, Hayat Özkanay, Fatma Demet Arslan, Mehmet Köseoğlu","doi":"10.11613/BM.2025.010706","DOIUrl":"10.11613/BM.2025.010706","url":null,"abstract":"<p><strong>Introduction: </strong>Biological variation (BV) data are necessary for interpretation of test results and assessment of analytical performance. We aimed to determine the BV estimates for thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and free thyroxine(fT4) in healthy subjects in Turkey and compare them with the literature findings.</p><p><strong>Materials and methods: </strong>A total of 21 Turkish healthy volunteers (12 males and 9 females) were included in the study. Blood samples were collected once a week for five weeks, and the analysis was performed using the chemiluminescent immunoassay method on an Advia Centaur XP (Siemens Diagnostic, Tarrytown, USA). Analytical variation (CV_A), within-subject BV (CV_I) and between-subject BV (CV_G) were calculated. Analytical goals, individuality index (II) and reference change value (RCV) were derived from these data. Statistical analysis was performed using BioVar: BV analysis tool v.1.0.</p><p><strong>Results: </strong>For TSH, fT3 and fT4, CV_A (confidence interval, CI) were 3.3% (2.9 to 3.8), 1.7% (1.5 to 1.9) and 2.7% (2.4 to 3.1); CV_I (CI) were 22.3% (19.3 to 26.3), 4.4% (3.8 to 5.3) and 5.1% (4.3 to 6.1); CV_G (CI) were 26.6% (19.2 to 39.8), 9.2% (6.9 to 13.6) and 8.2% (6.1 to 12.1), respectively. For TSH, fT3 and fT4, desirable total errors were 27.1%, 6.2% and 6.6%; II values were calculated as 0.84, 0.48 and 0.61; and RCV% values (decrease; increase) were - 40.3;67.6, - 10.4;11.6 and - 12.7;14.5, respectively.</p><p><strong>Conclusions: </strong>Our study provides updated BV data for thyroid function tests (TFTs) in healthy subjects in Turkey. As TFTs have shown a high degree of individuality, RCV should be preferred rather than population-based reference ranges in the assessment of serum concentrations. Our BV estimates were compatible with European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) BV meta-analysis data obtained using different immunoassay methods in different populations.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010706"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red blood cell agglutination caused by ceftriaxone and its effect on erythrocyte parameters: a case report.","authors":"Petra Andrasic, Renata Zrinski Topic, Ivan Pavic, Jasna Lenicek Krleza","doi":"10.11613/BM.2025.011002","DOIUrl":"10.11613/BM.2025.011002","url":null,"abstract":"<p><p>Ceftriaxone, a widely used antibiotic, is one of the most common drugs to cause drug-induced immune hemolytic anemia. In this report, we describe the effect of ceftriaxone on red blood cell parameters (low red blood cell count, low hematocrit, and high erythrocyte index values) in two pediatric patients without clinical symptoms of hemolytic anemia. Although automated hematology analyzers have helped to detect incorrect results, a peripheral blood smear examination was necessary for recognizing the erythrocyte agglutinins caused by ceftriaxone. Serological testing was not possible, but the resulting drug-induced antibodies mimicked cold agglutinins in the first patient and warm agglutinins in the second patient. Timely reactions and corresponding laboratory procedures prevented potential complications due to drug administration. This report aims to present laboratory findings and preanalytical challenges in these cases and share our experiences in solving them.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"011002"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are we ready to integrate advanced artificial intelligence models in clinical laboratory?","authors":"Slavica Dodig, Ivana Čepelak, Matko Dodig","doi":"10.11613/BM.2025.010501","DOIUrl":"10.11613/BM.2025.010501","url":null,"abstract":"<p><p>The application of advanced artificial intelligence (AI) models and algorithms in clinical laboratories is a new inevitable stage of development of laboratory medicine, since in the future, diagnostic and prognostic panels specific to certain diseases will be created from a large amount of laboratory data. Thanks to machine learning (ML), it is possible to analyze a large amount of structured numerical data as well as unstructured digitized images in the field of hematology, cytology and histopathology. Numerous researches refer to the testing of ML models for the purpose of screening various diseases, detecting damage to organ systems, diagnosing malignant diseases, longitudinal monitoring of various biomarkers that would enable predicting the outcome of each patient's treatment. The main advantages of advanced AI in the clinical laboratory are: faster diagnosis using diagnostic and prognostic algorithms, individualization of treatment plans, personalized medicine, better patient treatment outcomes, easier and more precise longitudinal monitoring of biomarkers, <i>etc</i>. Disadvantages relate to the lack of standardization, questionable quality of the entered data and their interpretability, potential over-reliance on technology, new financial investments, privacy concerns, ethical and legal aspects. Further integration of advanced AI will gradually take place on the basis of the knowledge of specialists in laboratory and clinical medicine, experts in information technology and biostatistics, as well as on the basis of evidence-based laboratory medicine. Clinical laboratories will be ready for the full and successful integration of advanced AI once a balance has been established between its potential and the resolution of existing obstacles.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010501"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers.","authors":"Gramos Begolli, Maja Lukić, Lada Rumora, Lorna Čorak, Andrea Vukić Dugac, Marko Jakopović, Miroslav Samaržija, Ilijan Tomaš, Jelena Knežević, Željko Debeljak","doi":"10.11613/BM.2025.011201","DOIUrl":"https://doi.org/10.11613/BM.2025.011201","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.11613/BM.2025.010702.].</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"011201"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the stability of ACTH in whole blood a genuine concern during the preanalytical phase? A systematic review.","authors":"Ahmad Dib, Damien Leleu, Stéphanie Lemaire, Laurence Duvillard, Louise Ménégaut, Damien Denimal","doi":"10.11613/BM.2025.010502","DOIUrl":"10.11613/BM.2025.010502","url":null,"abstract":"<p><p>Adrenocorticotropic hormone (ACTH) has historically been considered an unstable hormone after venous sampling, necessitating stringent conditions for the transport of blood samples to the laboratory to ensure accurate measurement. However, recent investigations suggest that ACTH may be more stable than previously assumed, raising the possibility of more flexible handling conditions. This prompted us to conduct a systematic review using the MEDLINE database to ascertain the stability of ACTH in blood samples. We included 9 studies in our final analysis from 405 reports. Our findings reveal that all studies reported a mean percentage difference (PD%) in ACTH concentrations relative to baseline below the 10% threshold when uncentrifuged tubes were stored under refrigerated conditions for 2, 4, 6, and 8 hours. In contrast, the mean PD% exceed the 10% threshold in 5 out of 7 studies investigating a storage duration of 24 hours under refrigerated conditions. Nearly all studies reported a mean PD% in ACTH concentrations relative to baseline below 10% when uncentrifuged tubes were stored at room temperature for 2, 4, and 6 hours. However, for storage durations of 8, 12, and 24 hours at room temperature, most studies observed a mean PD% exceeding 10%. In summary, our findings suggest that ACTH remains stable in uncentrifuged tubes containing EDTA for 6 h at room temperature and at least 8 h under refrigerated conditions. Our findings can assist clinical laboratories in reviewing their acceptance criteria for sample transport regarding time and temperature.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010502"},"PeriodicalIF":1.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling sphingolipid dynamics in late-onset preeclampsia: insights from lipidomic analysis.","authors":"Tamara Antonic, Sandra Vladimirov, Daniela Ardalic, Milica Miljkovic-Trailovic, Marija Saric-Matutinovic, Tamara Gojkovic, Jelena Munjas, Jasmina Ivanisevic, Snezana Jovicic, Jelena Vekic, Aleksandra Zeljkovic, Zeljko Mikovic, Aleksandra Stefanović","doi":"10.11613/BM.2025.010708","DOIUrl":"10.11613/BM.2025.010708","url":null,"abstract":"<p><strong>Introduction: </strong>Sphingolipids, essential to trophoblast and endothelial function, may impact inflammation in preeclampsia. However, their specific role in late-onset preeclampsia remains unclear. To address this research gap, we analyzed sphingolipid profiles in pregnancies at high risk for preeclampsia development to identify potential biomarkers and clarify their role in disease pathogenesis.</p><p><strong>Materials and methods: </strong>We monitored 90 pregnant women at high risk for preeclampsia development across four gestational points. These women were later categorized into the group of women with high risk who did not develop preeclampsia (HRG) (70 women) or the preeclampsia group (PG) (20 women). Sphingolipids (sphingosine, sphinganine, sphingosine-1-phosphate (S1P), ceramides C16:0/C24:0, and sphingomyelin C16:0) were quantified via liquid chromatography-tandem mass spectrometry.</p><p><strong>Results: </strong>Sphingolipid profiles revealed distinct patterns between groups. Concentrations of S1P in the HRG increased from the 1st trimester to delivery (P < 0.001). We did not notice significant changes in S1P during pregnancy in the PG but compared with the HRG we found significantly lower concentrations at each test point from the 2nd trimester until delivery (P = 0.020, P = 0.013, P = 0.011, respectively). Ceramides C16:0 and C24:0 demonstrated significant increases over time in HRG (P < 0.001, both). Sphingomyelin C16:0 increased significantly across pregnancy in both groups (P < 0.001 in HRG and P = 0.006 in PG), with no significant differences between groups.</p><p><strong>Conclusions: </strong>We identified S1P as a potential biomarker for late-onset preeclampsia, with lower concentrations observed in PG compared to HRG. Rising sphingomyelin concentrations in both cohorts might serve as a relevant cardiovascular risk indicator in pregnancies at high risk for preeclampsia.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"35 1","pages":"010707"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}